Related Experiment Video

Updated: Feb 26, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Cyclooxygenase-2 Inhibition Enhances Proliferation of NKT Cells Derived from Patients with Laryngeal Cancer

Janusz Klatka1, Ewelina Grywalska2, Anna Hymos1

  • 1Department of Otolaryngology and Laryngeal Oncology, Medical University of Lublin, Lublin, Poland.

Anticancer Research
|July 26, 2017
PubMed
Abstract

Insights

Inhibition of cyclooxygenase-2 (COX-2) enhances natural killer T (NKT) cell proliferation in laryngeal cancer (LC) patients. This suggests COX-2 inhibition is a potential immunotherapy-enhancing tool for LC treatment.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Laryngeal cancer (LC) poses a significant health challenge.
  • Natural killer T (NKT) cells play a crucial role in immune responses.
  • Dendritic cells (DCs) are key players in cancer immunotherapy.

Purpose of the Study:

  • To investigate the role of cyclooxygenase-2 (COX-2) inhibition by celecoxib in enhancing NKT cell proliferation.
  • To evaluate the potential of this enhancement in dendritic cell (DC)-based laryngeal cancer (LC) immunotherapy.

Main Methods:

  • Peripheral blood mononuclear cells were collected from 48 LC patients and 30 controls.
  • In vitro generation of DCs using neoplastic cell lysates.
  • NKT cell proliferation was assessed using a 3H-thymidine incorporation assay.

Main Results:

  • NKT cell proliferation was lower in LC patients compared to controls.
  • COX-2 inhibition significantly enhanced NKT cell proliferation when stimulated with autologous DCs in LC patients.
  • Higher NKT cell proliferation rates were observed in non-metastatic and highly differentiated LC.

Conclusions:

  • COX-2 inhibition demonstrates potential as an immunotherapy-enhancing tool for laryngeal cancer.
  • Targeting COX-2 may improve the efficacy of DC-based immunotherapy for LC.
Keywords:
NKT cellscyclooxygenase-2 inhibitordendritic cellsproliferation

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

11.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.7K